Cargando…

Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier

BACKGROUND: Acute graft-versus-host disease (aGVHD) initiated by intestinal barrier dysfunction and gut microbiota dysbiosis, remains one of the main obstacles for patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) to achieve good prognosis. Studies have suggested that...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, Xiaoyin, Pan, Weifeng, Wang, Junhui, Liu, Liping, Yin, Zhao, Jin, Hua, Liu, Qifa, Zheng, Lei, Sun, Haitao, Gao, Ya, Ping, Baohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461746/
https://www.ncbi.nlm.nih.gov/pubmed/37645691
http://dx.doi.org/10.2147/JIR.S420747
_version_ 1785097905900617728
author Bu, Xiaoyin
Pan, Weifeng
Wang, Junhui
Liu, Liping
Yin, Zhao
Jin, Hua
Liu, Qifa
Zheng, Lei
Sun, Haitao
Gao, Ya
Ping, Baohong
author_facet Bu, Xiaoyin
Pan, Weifeng
Wang, Junhui
Liu, Liping
Yin, Zhao
Jin, Hua
Liu, Qifa
Zheng, Lei
Sun, Haitao
Gao, Ya
Ping, Baohong
author_sort Bu, Xiaoyin
collection PubMed
description BACKGROUND: Acute graft-versus-host disease (aGVHD) initiated by intestinal barrier dysfunction and gut microbiota dysbiosis, remains one of the main obstacles for patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) to achieve good prognosis. Studies have suggested that mesenchymal stem cells (MSCs) can suppress immune responses and reduce inflammation, and human leukocyte antigen-G5 (HLA-G5) plays an important role in the immunomodulatory effects of MSCs, but very little is known about the potential mechanisms in aGVHD. Thus, we explored the effect of HLA-G5 on the immunosuppressive properties of human amnion MSCs (hAMSCs) and demonstrated its mechanism related to the gut microbiota at the intestinal barrier in aGVHD. METHODS: Patients undergoing allo-HSCT were enrolled to detect the levels of plasma-soluble HLA-G (sHLA-G) and regulatory T cells (Tregs). Humanized aGVHD mouse models were established and treated with hAMSCs or HLA-G5 overexpressing hAMSCs (ov-HLA-G5-hAMSCs) to explore the mechanism of HLA-G5 mediated immunosuppressive properties of hAMSCs and the effect of ov-HLA-G5-hAMSCs on the gut microbiota at the intestinal barrier in aGVHD. RESULTS: The plasma levels of sHLA-G on day +30 after allo-HSCT in aGVHD patients were lower than those in patients without aGVHD, and the sHLA-G levels were positively correlated with Tregs percentages. ov-HLA-G5-hAMSCs had the potential to inhibit the expansion of CD3+CD4+ T and CD3+CD8+ T cells and promote Tregs differentiation, suppress proinflammatory cytokine secretion but promote anti-inflammatory cytokines release. Besides, ov-HLA-G5-hAMSCs also could reverse the intestinal barrier dysfunction and gut microbiota dysbiosis in aGVHD. CONCLUSION: We demonstrated that HLA-G might work with Tregs to create a regulatory network together to reduce the occurrence of aGVHD. HLA-G5 mediated hAMSCs to exert higher immunosuppressive properties in vivo and reverse the immune imbalance caused by T lymphocytes and cytokines. Furthermore, HLA-G5 overexpressing hAMSCs could restore gut microbiota and intestinal barriers, thereby ameliorating aGVHD.
format Online
Article
Text
id pubmed-10461746
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104617462023-08-29 Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier Bu, Xiaoyin Pan, Weifeng Wang, Junhui Liu, Liping Yin, Zhao Jin, Hua Liu, Qifa Zheng, Lei Sun, Haitao Gao, Ya Ping, Baohong J Inflamm Res Original Research BACKGROUND: Acute graft-versus-host disease (aGVHD) initiated by intestinal barrier dysfunction and gut microbiota dysbiosis, remains one of the main obstacles for patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) to achieve good prognosis. Studies have suggested that mesenchymal stem cells (MSCs) can suppress immune responses and reduce inflammation, and human leukocyte antigen-G5 (HLA-G5) plays an important role in the immunomodulatory effects of MSCs, but very little is known about the potential mechanisms in aGVHD. Thus, we explored the effect of HLA-G5 on the immunosuppressive properties of human amnion MSCs (hAMSCs) and demonstrated its mechanism related to the gut microbiota at the intestinal barrier in aGVHD. METHODS: Patients undergoing allo-HSCT were enrolled to detect the levels of plasma-soluble HLA-G (sHLA-G) and regulatory T cells (Tregs). Humanized aGVHD mouse models were established and treated with hAMSCs or HLA-G5 overexpressing hAMSCs (ov-HLA-G5-hAMSCs) to explore the mechanism of HLA-G5 mediated immunosuppressive properties of hAMSCs and the effect of ov-HLA-G5-hAMSCs on the gut microbiota at the intestinal barrier in aGVHD. RESULTS: The plasma levels of sHLA-G on day +30 after allo-HSCT in aGVHD patients were lower than those in patients without aGVHD, and the sHLA-G levels were positively correlated with Tregs percentages. ov-HLA-G5-hAMSCs had the potential to inhibit the expansion of CD3+CD4+ T and CD3+CD8+ T cells and promote Tregs differentiation, suppress proinflammatory cytokine secretion but promote anti-inflammatory cytokines release. Besides, ov-HLA-G5-hAMSCs also could reverse the intestinal barrier dysfunction and gut microbiota dysbiosis in aGVHD. CONCLUSION: We demonstrated that HLA-G might work with Tregs to create a regulatory network together to reduce the occurrence of aGVHD. HLA-G5 mediated hAMSCs to exert higher immunosuppressive properties in vivo and reverse the immune imbalance caused by T lymphocytes and cytokines. Furthermore, HLA-G5 overexpressing hAMSCs could restore gut microbiota and intestinal barriers, thereby ameliorating aGVHD. Dove 2023-08-24 /pmc/articles/PMC10461746/ /pubmed/37645691 http://dx.doi.org/10.2147/JIR.S420747 Text en © 2023 Bu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Bu, Xiaoyin
Pan, Weifeng
Wang, Junhui
Liu, Liping
Yin, Zhao
Jin, Hua
Liu, Qifa
Zheng, Lei
Sun, Haitao
Gao, Ya
Ping, Baohong
Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
title Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
title_full Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
title_fullStr Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
title_full_unstemmed Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
title_short Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
title_sort therapeutic effects of hla-g5 overexpressing hamscs on agvhd after allo-hsct: involving in the gut microbiota at the intestinal barrier
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461746/
https://www.ncbi.nlm.nih.gov/pubmed/37645691
http://dx.doi.org/10.2147/JIR.S420747
work_keys_str_mv AT buxiaoyin therapeuticeffectsofhlag5overexpressinghamscsonagvhdafterallohsctinvolvinginthegutmicrobiotaattheintestinalbarrier
AT panweifeng therapeuticeffectsofhlag5overexpressinghamscsonagvhdafterallohsctinvolvinginthegutmicrobiotaattheintestinalbarrier
AT wangjunhui therapeuticeffectsofhlag5overexpressinghamscsonagvhdafterallohsctinvolvinginthegutmicrobiotaattheintestinalbarrier
AT liuliping therapeuticeffectsofhlag5overexpressinghamscsonagvhdafterallohsctinvolvinginthegutmicrobiotaattheintestinalbarrier
AT yinzhao therapeuticeffectsofhlag5overexpressinghamscsonagvhdafterallohsctinvolvinginthegutmicrobiotaattheintestinalbarrier
AT jinhua therapeuticeffectsofhlag5overexpressinghamscsonagvhdafterallohsctinvolvinginthegutmicrobiotaattheintestinalbarrier
AT liuqifa therapeuticeffectsofhlag5overexpressinghamscsonagvhdafterallohsctinvolvinginthegutmicrobiotaattheintestinalbarrier
AT zhenglei therapeuticeffectsofhlag5overexpressinghamscsonagvhdafterallohsctinvolvinginthegutmicrobiotaattheintestinalbarrier
AT sunhaitao therapeuticeffectsofhlag5overexpressinghamscsonagvhdafterallohsctinvolvinginthegutmicrobiotaattheintestinalbarrier
AT gaoya therapeuticeffectsofhlag5overexpressinghamscsonagvhdafterallohsctinvolvinginthegutmicrobiotaattheintestinalbarrier
AT pingbaohong therapeuticeffectsofhlag5overexpressinghamscsonagvhdafterallohsctinvolvinginthegutmicrobiotaattheintestinalbarrier